Rite Aid Corp (RAD)
$7.57 0.29 (3.69%)
19:32 EST RAD Stock Quote Delayed 15 Minutes
Previous Close $7.57
Market Cap 8.08B
PE Ratio -22.26
Volume (Avg. Vol.) 1.78M
Day's Range 7.50 - 7.88
52-Week Range 0.43 - 11.58
Dividend & Yield N/A (N/A)
RAD Stock Predictions, Articles, and Rite Aid Corp News
- From InvestorPlace
- From the Web
These stocks to sell will likely face pain in 2020 as these equities face worsening conditions and increasing financial and market pressure.
These 5 stocks all have a real chance of winding up at zero — but if they can avoid that outcome, they could easily triple or more.
Wednesday's 3 big stock charts highlight recent market winners whose rallies may be petering out.
By Ian Cooper
RAD stock hasn't benefited when management gave up selling electronic cigarettes while taking on CBD products. That's not the turnaround strategy it needs.
Believe it or not, Rite Aid has the opportunity to maximize its revenue profile. But getting there is a herculean task, leaving Rite Aid stock an avenue best left for speculators.
Alphabet saved FIT stock with a big buyout, and these five stocks to buy could be next to be saved by an acquisition.
These eight penny stocks have gone from winners to losers, and while some of them could go back to being winners, not all of them will.
RAD stock both rallied by 50% and dropped by 30% in September - and none of it had anything to do with the fundamentals of Rite Aid stock, which remain bad.
Rite Aid stock – don’t wait for any management-led turnaround. This pharmacy retailer is laden with debt, cash flow losses and no clear turnaround plan.
Rather than trying desperately to find a buyer, Rite Aid will leverage their core strengths to bring value-add to their business. This is probably the best play available for Rite Aid stock.
By Thomas Niel
With this in mind, the stock is a hard pass. Investors likely can find more solid turnaround plays elsewhere. Given the volatility in the RAD stock prices, shares could shoot higher on speculation. But long term, Rite Aid stock is not a strong investment opportunity.
Rite Aid (NYSE:RAD) jumped more than 20% last week after exceeding second-quarter earnings guidance. The boost came at a good time. Rite Aid stock has....
Rite Aid (RAD) earnings for the second quarter of fiscal 2020 have RAD stock taking off on Thursday on a strong EPS beat.
With Rite Aid reporting Q2 earnings on Thursday, all eyes will focus on the pharmacy retailer’s forward guidance. Unfortunately, that might not be a good thing for RAD stock.
Rite Aid stock has a chance of recovering but the new CEO has plenty of work ahead. The company must grow prescription volumes and sales.
It was a slow session in the stock market today, with little gains showing up on Monday. Here's what happened in the U.S. stock market.
RAD stock looks tempting here in the midst of this lull, but what Rite Aid needs to do the most is the one thing that will be toughest to do.
With the RAD stock price down 95%, value investors might be intrigued. But there are better risk-adjusted plays than Rite Aid stock.
Wednesday’s Highlights at Noon: Clovis Oncology (CLVS), Dynavax (DVAX), Rite Aid (RAD), Novagold Resources New (NG), Skyworks Solutions (SWKS)
From Analyst Ratings
So far Wednesday, December 11, NASDAQ is up 0.72% and the S&P is down -0.26%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Clovis Oncology (CLVS – Research Report), Dynavax (DVAX – Research Report), Rite Aid (RAD – Research Report), Novagold Resources New (NG – Research Report) and
Navellier RatingsPowered by Portfolio Grader